How to funnel your therapeutic through in silico, in vitro, ex vivo, and in vivo model systems in an intelligent way, reducing timelines and maximizing data value
Use in vitro models to uncover genetic signatures of response and guide in vivo model selection for further validation
Explore drug mechanism of action using patient-derived xenografts (PDX) enabling clinical-preclinical data corroboration
Translate preclinical biomarkers into the clinic, and how this enables the identification and stratification of relevant patient populations
Viability of decreasing secondary mutations by disruption of cell division cycle using eflornithine
Effect of TMZ on increasing frequency of mutations in U87MG glioblastoma cells while DMFO treated cells showed mutation frequency statistically similar to that of the untreated cells
DMFO may inhibit progression of DNA mutations caused by alkylating chemotherapy agents such as TMZ
Advantages to biobanks, pharma and biotech using SNP based assay and barcode deep NGS sequencing, to enable internal quality control for frequent surveillance of mouse and human samples, cell lines, organoids, xenograft models, and patient tissues
The identity of mouse and human cell lines and models and misidentified cell lines
Mycoplasma and viral contamination that pose risks for research and lab safety
Intra- and mouse-human interspecies contamination with 1-2% sensitivity
Cross-contamination of your mouse and human cell lines and detection of mouse stromal invasion of xenograft tumors
Annotation of human preclinical and RUO samples with gender and race information
Methods that can make the design and analysis of MCTs more rational, flexible and powerful
Methods that make MCTs a better tool in oncology research and drug development
Statistical framework developed to provide general guidelines on the design, analysis and application of MCTs.
The advantages of Linear mixed models (LMMs) and frailty models for survival analysis, used in discovering biomarkers and exploring drug mechanisms of action
Advantages of making data driven decisions using our range of genomics capabilities, next generation sequencing (NGS) services and cutting-edge data analysis platforms
Genetic features associated with drug response utilizing our historical datasets, and applying our proprietary algorithm for biomarker discovery
Expansive model datasets, including our large database of NGS-characterized models
Genes associated with tumor immunity using our Mouse I/O RNA-Seq Panel
Two-drug combination effects of synergistic, antagonistic, and additive cell-based assays
Two common types of drug combination experimental designs: Fixed Ratio: constant concentration ratio and Matrix Ratio: variable concentration ratios
Dosing data from your existing assays or work with our experts to design a study, taking advantage of CrownBio’s well-validated cell lines and variety of assay options